pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,839 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1873Endpoints1452Fierce Biotech770BioSpace761BioPharma Dive549raps249onclive165fda recalls
therapy area
allOncology12944Rare Disease3351Immunology3026Cardiology2859Hematology2302Pulmonology2255Vaccines
  • J&J buys Ollin Biosciences for $2.2 billion, taps Blackstone for $750 million Phase 3 eye drug funding
    Johnson & Johnson announced it will acquire Texas‑based ophthalmology biotech Ollin Biosciences, paying $2.2 billion upfront for the company and its late‑stage bispecific antibody targeting retinal…
    BioSpace · 3d agoDealPositive↗ source
  • Eli Lilly to acquire Calytrix Bio for up to $1.5 billion to add blood-cancer assets
    Eli Lilly announced it will acquire privately held Calytrix Bio in a deal valued at up to $1.5 billion in cash. The acquisition is Lilly’s 14th buyout this year and adds a blood-cancer program to…
    BioSpace · 3d agoDealPositive↗ source
← prev
page 3 of 74
next →
120
fda medwatch115
globenewswire health73
fda press62
1854
Psychiatry & CNS1234
Ophthalmology1136
Endocrinology & Metabolism809
Pain792
Nephrology787
  • FDA issues CRL for Summit Therapeutics' ivonescimab, underscoring need for overall survival data
    The FDA sent a complete response letter to Summit Therapeutics, rejecting its biologics license application for ivonescimab, a PD-1xVEGF antibody being tested in EGFR-mutated non-small cell lung ca…
    BioSpace · 3d agoCRLNegative↗ source
  • Eli Lilly to acquire Calytrix Bio for up to $1.5B, targeting rare blood cancers
    Eli Lilly announced it will acquire Calytrix Bio, a Massachusetts biotech, in a deal valued at up to $1.5 billion. Calytrix focuses on precision therapies for myeloproliferative neoplasms, includi…
    BioPharma Dive · 3d agoDealPositive↗ source
  • Seawolf Therapeutics raises $100M and secures up to $1.2B partnership with Sanofi for redosable DNA medicines
    Seawolf Therapeutics announced a $100 million Series A financing backed by investors including Novartis Venture Fund, Eli Lilly, CRISPR Therapeutics and others. The company also disclosed a multi‑…
    BioSpace · 3d agoDealPositive↗ source
  • Choosing the Right AI Infrastructure Is Key to Accelerating Future Drug Discoveries
    Scientific AI is reshaping drug discovery by allowing developers to predict molecule behavior and design new compounds using models trained on protein structures, genomic data, and experimental res…
    BioPharma Dive · 3d agoNeutral↗ source
  • Clinical AI pilots stall due to organizational environment, not technology
    Clinical teams are increasingly using artificial intelligence to draft regulatory paperwork, assist data review, shape trial design and interpret complex evidence. The technology is proving its val…
    BioPharma Dive · 3d agoNeutral↗ source
  • Seawolf Therapeutics raises $100M and secures up to $1.2B partnership with Sanofi
    Seawolf Therapeutics, a San Diego-based DNA-therapy startup, announced a $100 million financing round as it emerges from stealth. The round was led by Versant Ventures with participation from MPM…
    BioPharma Dive · 3d agoDealPositive↗ source
  • FDA rejects ivonescimab for lung cancer; J&J to acquire Ollin Biosciences for up to $3.3B, Senate votes on FDA commissioner
    The FDA has denied the application for ivonescimab as a treatment for lung cancer, halting its development for that indication. Johnson & Johnson announced a deal to purchase Ollin Biosciences, a…
    raps · 3d agoRegulatoryNeutral↗ source
  • Wave Life Sciences reports stronger weight-loss effect of WVE-007 in patients with higher BMI and excess body fat
    Wave Life Sciences presented data at ObesityWeek 2026 from its mid-stage INLIGHT trial of the investigational siRNA drug WVE-007. The analysis of three cohorts showed that participants with higher…
    BioSpace · 3d agoPositive readoutPositive↗ source
  • Sofinnova Partners raises €725M crossover fund to back later-stage European biotech firms
    Sofinnova Partners, a leading European life‑science venture firm, announced that it has closed a second crossover fund worth 725 million euros (about $815 million). The new vehicle, called Sofinnov…
    BioPharma Dive · 3d agoDealPositive↗ source
  • Emerging biotech hubs like India could help lower global drug costs by scaling development
    The article notes that every new therapy raises two core questions: can it be created and can society afford it. Historically biotech has focused on the first question. The author argues that as s…
    BioSpace · 3d agoNeutral↗ source
  • Biopharma firms showcase non-amyloid Alzheimer’s strategies at CTAD 2026 conference
    Biopharma companies including Biogen, Bristol Myers Squibb and Roche gathered in Boston for the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference, where they presented new data on their…
    BioSpace · 3d agoPositive↗ source
  • Novartis and BMS pause autoimmune CAR-T trials after patient deaths and safety concerns
    Novartis, Bristol Myers Squibb and several other biotech firms have recently encountered setbacks while developing therapies for autoimmune diseases. Some programs have been completely discontinued…
    BioSpace · 3d agoNegative readoutNegative↗ source
  • Industry groups push for clearer FDA guidance on ANDA and 505(b)(2) filings amid rising patent thickets
    Industry trade groups representing brand‑name and generic manufacturers have asked the FDA to clarify its recent guidance on when a company should file an abbreviated new drug application (ANDA) ve…
    raps · 3d agoRegulatoryNeutral↗ source
  • Canadian biotech firms turn to Europe as US political uncertainty creates new market opportunities
    At BIO-Europe in Cologne, Canadian companies said shifting US politics are prompting them to look to European partners. They highlight Canada’s regulatory speed and economic incentives as advantag…
    BioSpace · 3d agoPositive↗ source
  • New polymer lidding technologies aim to make pharmaceutical blister packs fully recyclable
    Pharmaceutical manufacturers are increasingly prioritizing sustainability in material selection, packaging design and end-of-life handling. The goal is to lower environmental impact while keeping p…
    BioPharma Dive · 3d agoPositive↗ source
  • BridgeBio's Morgan Paull and Christine Zhang Named BioSpace 40 Under 40, Emphasize Patient-Centric Model
    BridgeBio has seen two of its young executives, Morgan Paull and Christine Zhang, named to BioSpace’s 2026 40 Under 40 list. Their inclusion highlights the company’s rapid growth and focus on rare-…
    BioSpace · 3d agoPositive↗ source
  • Experts discuss AI applications and challenges in regulatory conformity assessments
    At a recent RAPS AI in Regulatory Conference in Barcelona, a panel of experts examined how artificial intelligence is being adopted in conformity assessment processes. Participants noted that noti…
    raps · 3d agoRegulatoryNeutral↗ source
  • Australian regulator seeks feedback on adding unique device IDs to medical device free‑sale certificates
    Australia’s Therapeutic Goods Administration (TGA) announced it is reviewing whether to include unique device identification (UDI) details on certificates of free sale that accompany medical device…
    raps · 3d agoRegulatoryNeutral↗ source
  • FDA denies Summit Therapeutics' ivonescimab for EGFR-mutated lung cancer, halting US entry
    The U.S. Food and Drug Administration issued a complete response letter rejecting Summit Therapeutics' biologics license application for ivonescimab, a PD-1xVEGF bispecific antibody intended for EG…
    BioSpace · 4d agoCRLNegative↗ source
  • PharmaLogic acquires Lantheus radiopharma CDMO and New Jersey plant to launch transatlantic manufacturing platform
    PharmaLogic announced it will purchase Lantheus' radiopharmaceutical contract development and manufacturing organization (CDMO) along with a production plant in Springfield, New Jersey. Lantheus h…
    BioSpace · 5d agoDealNeutral↗ source
  • Novo files US and EU approval for etavopivat, its $1B acquired sickle-cell therapy
    Novo submitted regulatory applications in the United States and Europe for etavopivat, a sickle cell disease therapy it bought from Forma Therapeutics in a $1 billion transaction. The company says…
    BioPharma Dive · 6d agoApprovalPositive↗ source
  • Neuroscience startups attract $450M in recent funding, Oyster Therapeutics secures $60M Series A
    Venture capital activity around neuroscience has picked up again, with five neurology-focused startups collectively raising about $450 million in the past few weeks. Data from BioPharma Dive show…
    BioPharma Dive · 6d agoDealPositive↗ source
  • Swiss biotech Windward Bio raises $175 million in IPO to fund lung-drug development and test Tezspire competitor
    Windward Bio, a Swiss immune‑drug developer, completed a $175 million initial public offering, selling about 10.3 million shares at $17 each. The company began trading on the exchange under the tic…
    BioPharma Dive · 6d agoDealPositive↗ source